Tuberculosis (TB), although preventable and curable, remains a global health threat. An estimated 10.6 million people fell ill with TB in 2022, resulting in an estimated 1.3 million deaths worldwide, far from the 2025 milestone of the End TB Strategy by the WHO. Moreover, anti-TB drug resistance,particularly MDR-TB (resistant to RIF & INH), is increasingly challenging the global TB treatment and prevention.
Efficient and accurate TB and anti-TB drug resistance diagnosis is the KEY to the success of TB treatment and prevention.
Our Solution
Marco & Micro-Test’s 3-in-1 TB Detection for TB infection/RIF & NIH Resistance Detection Kit enables efficient diagnosis of TB and RIF/INH in one detection by Melting curve technology.
3-in-1 TB/MDR-TB detection determining TB infection and key first-line drugs (RIF/INH) resistance enables timely and accurate TB treatment.
Successfully realizes the triple TB testing (TB infection, RIF & NIH Resistance) in one detection!
Rapid result: Available in 2-2.5 hrs with automatic result interpretation minimizing technical training for operation;
Test Sample: Sputum, L-J Medium, MGIT Medium, Bronchial Lavage Fluid;
High Sensitivity: 110 bacteria/mL for TB, 150 bacteria/mL for RIF resistance, 200 bacteria/mL for INH resistance, ensuring reliable detection even at low bacterial loads.
Multiple Targets: TB-IS6110; RIF-resistance-rpoB (507~533); INH-resistance-InhA, AhpC, katG 315;
Quality Validation: Internal control for sample quality validation to reduce false negatives;
Wide Compatibility: Compatibility with most mainstream PCR systems for wide lab accessibility (SLAN-96P , BioRad CFX96);
WHO Guidelines Compliance: Adhering to WHO guidelines for the management of drug-resistant tuberculosis, ensuring reliability and relevance in clinical practice.
Post time: Sep-19-2024